Mohammad Azab

Track

Insider profile

Currently holds positions in Astex Pharmaceuticals Inc and Xenon Pharmaceuticals Inc

Performance

Overall performance
3.8
Performance over holding periods
3.8
30 days 90 days 120 days
Average return 38% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
10 90% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Medical Officer Astex Pharmaceuticals Inc July 21, 2009 -
Independent Director Xenon Pharmaceuticals Inc Oct. 1, 2003 -
Mohammad Azab's trades of DURECT Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2022-05-25 2022-05-24
US DURECT Corp (DRRX)
B Purchase
16,811 +9.1%
321.01
US$558,378 		16,811 +9.1% 321.01 US$558,378
2022-05-25 2022-05-24
US DURECT Corp (DRRX)
B Purchase
15,477 +39.5%
137.81
US$1,998,147 		15,477 +39.5% 137.81 US$1,998,147
2022-05-25 2022-05-24
US DURECT Corp (DRRX)
B Purchase
39,169 -39.7%
496.06
US$2,088,811 		39,169 -39.7% 496.06 US$2,088,811
2022-05-25 2022-05-24
US DURECT Corp (DRRX)
B Purchase
5,000 +14.3%
0.39
US$1,942 		5,000 +14.3% 0.39 US$1,942
2022-05-25 2022-05-24
US DURECT Corp (DRRX)
B Purchase
5,000 +16.7%
0.39
US$1,962 		5,000 +16.7% 0.39 US$1,962
2022-05-18 2022-05-17
US DURECT Corp (DRRX)
B Purchase
1,800 +6.4%
0.42
US$758 		1,800 +6.4% 0.42 US$758
2022-05-18 2022-05-17
US DURECT Corp (DRRX)
B Purchase
8,900 +46.1%
0.42
US$3,749 		8,900 +46.1% 0.42 US$3,749
2022-05-18 2022-05-17
US DURECT Corp (DRRX)
B Purchase
9,300 +93.0%
0.42
US$3,899 		9,300 +93.0% 0.42 US$3,899
2022-05-18 2022-05-16
US DURECT Corp (DRRX)
B Purchase
10,000 +inf%
0.38
US$3,767 		10,000 +inf% 0.38 US$3,767
2019-09-17 2019-09-13
S Sale
23 -0.0%
9.31
US$214 		23 -0.0% 9.31 US$214